5-year clinical and radiographic follow-up of the uncemented Symax hip stem in an international study by Kruijntjens, Dennis Silvester Maria Gerardus et al.
Syddansk Universitet
5-year clinical and radiographic follow-up of the uncemented Symax hip stem in an
international study
Kruijntjens, Dennis Silvester Maria Gerardus; Kjærsgaard-Andersen, Per; Revald, Peter;
Leonhardt, Jane Schwartz; Arts, Jacobus Johannes Chris; ten Broeke, René Hendrikus Maria
Published in:
Journal of Orthopaedic Surgery and Research
DOI:
10.1186/s13018-018-0888-9
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Kruijntjens, D. S. M. G., Kjaersgaard-Andersen, P., Revald, P., Leonhardt, J. S., Arts, J. J. C., & ten Broeke, R.
H. M. (2018). 5-year clinical and radiographic follow-up of the uncemented Symax hip stem in an international
study. Journal of Orthopaedic Surgery and Research, 13(1), [191]. DOI: 10.1186/s13018-018-0888-9
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 25. Aug. 2018
RESEARCH ARTICLE Open Access
5-year clinical and radiographic follow-up
of the uncemented Symax hip stem in an
international study
Dennis Silvester Maria Gerardus Kruijntjens1* , Per Kjaersgaard-Andersen2, Peter Revald2,
Jane Schwartz Leonhardt2, Jacobus Johannes Chris Arts1 and René Hendrikus Maria ten Broeke1
Abstract
Background: The uncemented Symax hip stem is developed through optimization of the uncemented Omnifit hip
stem. The Symax stem design combines an anatomical anteverted proximal geometry with a straight distal section.
The proximal part is coated with a biomimetic hydroxyapatite (HA) coating for improved osseointegration to enhance
load transfer and to minimize proximal bone loss. The distal part is treated with an anodization surface treatment in
order to prevent distal bone apposition, which is expected to prevent distal loading and reduce proximal stress shielding.
Aim of this study is to report mid-term clinical performance and evaluate whether the radiographic features are in line
with the design principles of the Symax hip.
Methods: The biomimetic hydroxyapatite-coated uncemented Symax hip stem was evaluated in 80 patients during a
5-year prospective clinical international study. Harris Hip Score (HHS), Oxford Hip Score (OHS), and Western Ontario and
McMaster Universities Arthritis Index (WOMAC) were performed preoperatively and postoperatively at 6 months and 1,
2, 3 and 5 years. Anteroposterior radiographs of the pelvis and axial radiographs of the operated hips were evaluated
immediately postoperative and at follow-up 6 months and 1, 2, 3, and 5 years. Wilcoxon signed-rank test was used to
analyse whether clinical outcome scores changed statistically significant over time. The overall percentage of agreement
between two radiology assessment teams was used to evaluate observer agreement of radiology results. The Cohen’s
Kappa was evaluated as a measure of reliability to quantify the agreement between raters, corrected for chance agreement.
Results: Clinical outcome scores were excellent at 5 years with mean HHS of 98.1, mean OHS of 16.2 and mean WOMAC of
6.9. Only 2.7% of the patients had pain at rest or on weight-bearing, and mid-thigh pain was reported by 1.4% of the
patients after 5 years. The percentage of agreement between radiology assessment teams was 94 to 100%, except for
distal line formation (48%). Radiographic evaluation showed stable stems and signs of excellent progressive proximal
fixation and favourable bone remodeling.
Conclusions: The excellent mid-term clinical and radiographic performances are in line with the design principles and
coating properties of this new implant and earlier published results.
Trial registration: http://ClinicalTrials.gov, NCT03469687. Registered 19 March 2018 – Retrospectively registered.
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Background
New designs of uncemented hip stems focus on enhan-
cing osseointegration, improved interface sealing, opti-
mized load transfer, diminishing the rate of loosening,
and on improving clinical outcomes. For these purposes,
optimizations can be realized in the geometry of the
stem, the choice of material, surface texture, and the
type and extent of the osseointegrative coating [1–6].
These considerations resulted in the development of the
uncemented Symax stem design (Stryker Orthopaedics,
Amsterdam, the Netherlands) as an optimization of the
well-documented, second-generation uncemented
Omnifit hip stem [3, 7, 8]. Histological and histomor-
phometric analyses on retrieved implanted Symax hip
stems have already proven early proximal ingrowth as a
result of the new BONIT-hydroxyapatite (HA) coating
(DOT GmbH, Rostock, Germany) and the distal
DOTIZE surface treatment (DOT GmbH, Rostock,
Germany) [9]. Furthermore, improved bone remodeling
was already established in a 2-year follow-up dual-
energy X-ray absorptiometry (DEXA) study compared to
the Omnifit hip stem [10]. This international study is
part of a stepwise clinical introduction of the Symax hip
stem according to Malchau et al. [11], illustrating the
‘phased innovation’ of this new implant. As part of this
clinical introduction also, a prospective radiostereo-
metric analysis (RSA) study and a large prospective
clinical cohort study are ongoing. The aim of this study
is to report mid-term clinical performance and evaluate
whether the radiographic features are in line with the
design principles of the Symax hip stem in an inter-
national setting during 5 years of clinical follow-up in a
cohort of 80 patients.
It was hypothesized that the new BONIT-HA coating
and the distal DOTIZE surface treatment, together with
an optimized geometrical design, would generate both a
mechanically stable stem with mid-term radiographic
features of consistent and progressive excellent proximal
fixation and radiographic signs that would also underline
the effects of the distal surface treatment. The combination
of these would anticipate a superior bone remodeling that
is highly recognizable on conventional radiographs.
Methods
Between September 2004 and November 2005, 80 patients
were included in this prospective international study
performed at the Maastricht University Medical Centre
(MUMC), the Netherlands (centre 1, n = 30), and the Vejle
Hospital, Denmark (centre 2, n = 50). Eligibility criteria
were patients requiring primary uncemented total hip
arthroplasty (THA), age older than 18 years, and BMI less
or equal to 35. Exclusion criteria were bilateral hip
complaints, impaired cognitive function, and use of medi-
cation or illness influencing bone metabolism. Baseline
demographic data were similar for both study centres
(Table 1).
Ethical board approval was obtained from the local
Institutional Review Board (centre 1: METC 04-112;
centre 2: S-VF-20040133), and informed consent was
obtained from each patient prior to surgery. This study
was conducted according to the ethical standards of the
Declaration of Helsinki of 1975, as revised in 2013 in
Fortaleza (Brasil), and following the ISO 14155 Good
Clinical Practice (GCP) guidelines.
Surgical protocol
The posterolateral approach to the hip was used by four
senior hip surgeons. Patients received 24-h intravenous
antibiotic prophylaxis and deep venous thrombosis
prophylaxis with low molecular weight heparins. Full
weight-bearing was allowed from the first postoperative
day. In this study, complete excision of the joint capsule
was performed in 86.7% of the patients in centre 1
compared to 2.0% in centre 2. Non-steroidal anti-
inflammatory drug (NSAIDs) prescription to prevent
heterotopic bone formation also varied; 96.7% of the
patients in centre 1 received NSAIDs, compared to
only 4.0% of patients in centre 2.
Implant
The Symax hip stem is an uncemented design forged
from Ti6Al4V alloy. Primary mechanical stability is
provided by anatomical metaphyseal geometry, based on
CT-analysis of the proximal femur (data on file at
Stryker). The hip stem features a size-dependent ante-
version, neck length, and offset, with a centrum-collum-
diaphyseal (CCD) angle of 128° (data on file at Stryker).
Axial stability is pursued by the straight distal section in
the femoral canal (Fig. 1). Secondary biological stability
is accomplished by fast osseous integration due to the
BONIT-HA coating on the metaphyseal part of the stem
(Fig. 1), as was confirmed earlier by histology and histo-
morphometry analyses on retrieved stems [9]. BONIT-
HA is a new generation, electrochemically deposited,
biomimetic hydroxyapatite (HA) coating on top of a
commercially pure titanium plasma spray (TPS) layer. It
is deposited by low-temperature precipitation, is thin
(10–20 μm), and has a 3D surface with high porosity
(60%) and pore interconnectivity [9, 10, 12, 13]. The
coating is fully resorbable and is known to be substituted
by bone for about 99% [14]. The anodization surface
treatment, DOTIZE, applied on the distal part of the
stem, is an electrolytical conversion of the native oxide
film on titanium surfaces into a thicker and denser titan-
ium oxide. It shows anti-galling properties and reduces
protein adsorption with 19% and bone apposition com-
pared to untreated titanium alloy [9, 10, 15].
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The uncemented HA-coated Trident acetabular cup
(Stryker Orthopaedics, Mahwah, NJ, USA) was used in
78 patients (98%) [16], except 2 patients (2.5%) in centre
1 who had cemented SHP ArCom ultra-high molecular
weight polyethylene cups (Biomet, Bridgend, UK). Of
the 78 uncemented cups, 75 patients (96%) had a cer-
amic insert (Alumina) and 3 patients (3.8%) had a highly
cross-linked polyethylene insert. All patients had a cer-
amic head (Alumina). Head diameter of 32 mm was
used in 52 patients (65%), 28 mm in 14 patients (18%),
and 36 mm in 14 patients (18%).
Clinical evaluations
Clinical evaluations were performed preoperatively and
postoperatively at 6 months, 1 year, 2 years, 3 years, and
5 years. Evaluated clinical outcome parameters were a
hip-specific functional score (Harris Hip Score (HHS))
[17], a patient-centred hip score (Oxford Hip Score
(OHS)) [18], and a disease-specific quality-of-life outcome
measure (Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC)) [19]. Furthermore, the
incidence of thigh pain and overall pain at rest and on
weight-bearing was evaluated. The amount of pain was
classified as no pain, slight, mild, moderate, marked, or
totally disabling [17]. Complications and adverse events
were recorded during follow-up, and the resulting survival
analysis according to Kaplan-Meier was evaluated at the
final follow-up.
Radiographic evaluations
Anteroposterior radiographs of the pelvis and axial
radiographs of the operated hips were evaluated immedi-
ately postoperative and at follow-up 6 months, 1 year,
2 years, 3 years, and 5 years. Migration was assessed
according to the criteria of Malchau et al. [20]. Reactive
lines, cancellous condensation (‘spotwelds’), cortical
hypertrophy, and tip sclerosis were evaluated per Gruen
zone [21]. Implant fixation and stability was assessed
according to the modified Engh score [22]. Formation of
heterotopic bone was evaluated using Brooker’s classifi-
cation [23]. All radiographs were independently assessed
by two teams of each two observers (PKA, DK and RtB,
PR), consisting of one orthopaedic surgeon of both
centres. Both teams of observers were blinded for each
other’s assessment and the name and details of the
patient, as well as for the time of follow-up of the radio-
graphs. Furthermore, both teams evaluated 50 randomly
chosen radiographs to determine agreement and to
calculate intra-observer and inter-observer reliability.
When 95% agreement was established, each team evalu-
ated half of all radiographs of the total patient cohort.
Statistics
SPSS for Windows 17.0.1 (SPSS Inc., Chicago, Illinois,
USA) was used for statistical data analysis. Descriptive
statistics were used for patient characteristics. Pearson’s
chi-square test and Student’s t test were used to test
hypotheses between both study centres for categorical
variables and continuous variables respectively. Wilcoxon
Table 1 Baseline demographic data of study cohort
Centre 1 Centre 2 Total P value
No. of hips 30 50 80
Male/female 16/14 29/21 45/35 0.684
Mean (range) age (years) 57.5 (41–71) 56.2 (30–69) 56.7 (30–71) 0.437
Mean (range) BMI (kg/m2) 27.1 (20–33) 27.0 (18–35) 27.0 (18–35) 0.913
Diagnosis, no. of hips (%) 0.135
Osteoarthritis 27 (90.0%) 41 (82.0%) 68 (85.0%)
Avascular necrosis 2 (6.7%) 1 (2.0%) 3 (3.8%)
Posttraumatic arthritis 7 (14.0%) 7 (8.8%)
Other 1 (3.3%) 1 (2.0%) 2 (2.5%)
Fig. 1 Design features of Symax hip stem, illustrating the anatomically
anteverted proximal geometry and the distal posterior chamfer
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signed-rank test was used to analyse whether clinical out-
come scores changed statistically significant over time.
Statistical significance was set at p < 0.05. Results are re-
ported as means, with standard deviation (SD) or range
where relevant, or as frequencies. The overall percentage
of agreement was used to evaluate observer agreement of
radiology results [24]. The Cohen’s Kappa was evaluated
as a measure of reliability to quantify the agreement be-
tween raters, corrected for chance agreement. Kaplan-
Meier survival analysis was performed with revision for
any reason and with revision of stem for aseptic loosening
as the endpoints.
Results
After 5 years of clinical follow-up, 73 patients were eval-
uated. Follow-up was not completed by one patient
because of revision of both stem and cup for recurrent
dislocations, one patient had a revision of the insert for
squeaking, and five patients were lost to follow-up. One
of these patients moved to another geographic area, the
remaining four patients discontinued participation for
non-hip-related reasons; one patient was from centre 1,
and the remaining six patients from centre 2. Retro-
spective inquiry after a minimum 5-year follow-up
learned that there were no hip-related complaints and
no revision hip surgery was performed elsewhere.
Clinical evaluations
Mean HHS improved from 58.9 ± 12.0 preoperatively to
98.1 ± 6.1 at 5-year clinical follow-up, mean OHS im-
proved from 38.5 ± 6.0 preoperatively to 16.2 ± 6.4 after
5 years, and mean WOMAC improved from 48.2 ± 13.7
preoperatively to 6.9 ± 9.9 after 5 years of clinical
follow-up (Table 2). All clinical outcomes showed statis-
tically significant improvements between preoperative
and 6 months postoperative scores (p < 0.001), which
remained thereafter.
After 5 years, one patient (1.4%) complained of moder-
ate lateral thigh pain at rest and on weight-bearing. No
radiographic abnormalities could be detected for this pa-
tient. During follow-up, the number of patients with no,
or slight, pain at rest improved from 21.3% preoperatively
to 97.3% at 5 years. The number of patients with no, or
slight, pain on weight bearing also improved from 2.5%
preoperatively to 97.3% at 5 years.
Adverse events
During primary surgery, two patients developed an ace-
tabular fracture for which intraoperative interventions
were performed. These patients were not allowed imme-
diate full weight-bearing postoperatively. Four patients
had early dislocations, three of them were successfully
treated conservatively and the fourth patient underwent
revision of both cup and stem for a design with more
femoral offset. Conservative treatment of early disloca-
tions in our centres consisted of giving patients more
instructions about prohibited movements of deep flexion
and internal rotation, and we referred the patients back
to their physiotherapists. One patient developed an early
deep infection with Staphylococcus aureus 1 month after
primary surgery. This patient was successfully treated with
extensive debridement and with local and systemic anti-
biotic therapy. The implant could be retained. Finally, one
patient complained of squeaking for which revision of the
ceramic insert to a highly cross-linked polyethylene insert
(X3, Stryker Orthopaedics) was performed.
Survival of the Symax hip stem after 5 years with revi-
sion of the stem for any reason as the endpoint is 98.8%,
as only 1 patient of the initial 80 patients had a revision
of stem and cup for recurrent dislocations (Fig. 2). How-
ever, survival of the Symax stem is 100% after 5 years
with revision of the stem for loosening as the endpoint.
Radiographic evaluations
The percentage of agreement between both radiology
assessment teams for spotweld formation was 94%, with
a Cohen’s Kappa of 0.380. The percentage of agreement
between both radiology assessment teams for other
radiological evaluations was 100%, no Cohen’s Kappa
could be measured for these evaluations. Only distal line
formation could not be evaluated with high percentage
of agreement, which was calculated at 48%, with a
Cohen’s Kappa of 0.155.
Table 2 Mean clinical outcome parameters
Preoperative 6 months 1 year 2 years 3 years 5 years
Mean HHS (± SD) 58.9 (12.0) 94.3 (9.1) 95.2 (10.5) 96.1 (8.7) 97.4 (7.7) 98.1 (6.1)
Wilcoxon (P value) < 0.001 0.074 0.121 0.015 0.482
Mean OHS (± SD) 38.5 (6.0) 20.0 (9.4) 18.7 (8.1) 17.4 (7.7) 16.0 (7.1) 16.2 (6.4)
Wilcoxon (P value) < 0.001 0.028 0.072 0.012 0.081
Mean WOMAC (± SD) 48.2 (13.7) 13.0 (14.5) 10.8 (13.7) 9.7 (13.4) 9.0 (13.7) 6.9 (9.9)
Wilcoxon (P value) < 0.001 0.019 0.673 0.181 0.125
Mean HHS, OHS, and WOMAC with standard deviation (SD) and Wilcoxon ranked sign test evaluating improvement over time between two consecutive
follow-up moments
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Stem position was neutral for all stems. No osteolysis
or signs of proximal stress shielding were found during
follow-up. One patient (1.3%) showed distal migration of
the stem during follow-up. No lines or lucencies were
observed around the coated part of the prosthesis at any
follow-up time point. The appearance of extensive line
formation around the smooth, uncoated, distal part of
the stem increased from 10.5% after 6 months to 40% at
5 years. The appearance of distal line formation was
most common in Gruen zone 4, 5, and 6 and increased
during follow-up (Fig. 3). The appearance of spotwelds
increased from 63.2% at 6 months to 90.7% at 5 years,
only in the coated proximal Gruen zones 1 and 7 (Fig. 4).
Any degree of heterotopic ossifications (Brooker 1 to 4)
was seen in 29.7% of patients at 6 months; this number
increased to 40.5% at 5 years. Only one patient (1.4%)
showed Brooker 4 heterotopic ossification, which was
already present at 6 months.
Fig. 2 Kaplan-Meier curve for revision of stem for any reason, in years
Fig. 3 Outcomes of radiographic evaluation: reactive line formation
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Discussion
The purpose of this study was to evaluate clinical and
radiographic performance of the new uncemented
Symax hip stem in a 5-year international study, as part
of the ‘phased innovation’ of a new implant, and to
assess whether these outcomes were in line with the
design principles and coating properties of the Symax
hip stem. Our data showed excellent mid-term clinical
and radiographic performances and osseointegration of
the Symax hip stem at 5-year clinical follow-up with a
Kaplan-Meier survival of 98.8% with revision of the stem
for any reason as an endpoint.
The Symax hip stem leads to excellent clinical per-
formance as represented in HHS, OHS, and WOMAC
in this 5-year clinical follow-up study. Mean HHS of the
Symax hip stem is slightly better compared to the short-
and mid-term HHS of the Omnifit hip stem [3, 7, 8, 25,
26]. The Omnifit hip stem is another example of a prox-
imal press fit, HA-coated stem, on which geometry the
Symax was optimized. HHS of the Omnifit hip stem
during the first 3 years of clinical follow-up was 93 after
6 months, improving to 96 at 3 years [26] and stabilizing
to 93 after 6.4 years [27]. The clinical relevance of such
small differences in HHS however can be argued as
described by Poolman et al., who showed high intra-
observer variability for physical examination as part of
the HHS [28], and by Wamper et al. who showed limited
discriminating power of the HHS because of a ceiling
effect [29]. Nevertheless, the excellent HHS in this study
illustrates state of the art performance of the Symax hip
stem design.
According to Lieberman et al., we also conducted
patient-oriented quality-of-life surveys, like the OHS and
WOMAC [30, 31]. The OHS improved over time and
led to excellent scores postoperatively [18, 32]. Mean
WOMAC score showed the same pattern of improve-
ment over time as OHS [19], confirming high patient
satisfaction.
Another interesting observation of this study was that
the absence of pain at rest and during weight-bearing.
This was seen in 97.3% of the patients after 5 years,
while only 1.4% of the patients had moderate lateral
thigh pain. Although this result is only slightly better
than other contemporary implants based on the same
philosophy [8, 26, 27, 33–35], it is clearly superior to
older designs that follow different philosophies [36, 37].
This may be related to the distal geometry with posterior
chamfer to prevent stem tip impingement. Furthermore,
the prevention of distal fixation will also prevent con-
flicting elasticity issues between the stiffer implant and
the more flexible bone.
Longitudinal radiographic evaluations showed signs
of enhanced proximal fixation with the consistent ap-
pearance of spotwelds in Gruen zones 1 and 7, while
on the other hand, no radiolucencies or reactive lines
were seen in the coated part of the stem. These signs of
Fig. 4 Outcomes of radiographic evaluation: cancellous densification (‘spotwelds’)
Kruijntjens et al. Journal of Orthopaedic Surgery and Research  (2018) 13:191 Page 6 of 9
proximal fixation combined with increasing line forma-
tion around the distal uncoated part of the prosthesis
can be explained by the BONIT-HA coating and
DOTIZE surface treatment of the Symax hip stem. As
illustrated from histomorphometry analyses of retrieval
specimens, BONIT-HA coating results in osseointegra-
tion over a larger part of the coated stem surface [9,
14]. The highly bioactive biomimetic BONIT-HA coat-
ing results in both more extensive bone-implant con-
tact and bone density in periprosthetic regions of
interest compared to other currently known hydroxy-
apatite or porous-coated stems [9, 10]. Enhanced prox-
imal fixation combined with reduced distal bone
apposition, caused by the DOTIZE surface treatment,
leaves space for relative ‘micromotion’ between the stiff
distal stem and the more elastic bone [25]. This leads
to a so-called ‘windshield-wiper sign’ [33], causing in-
creasing occurrence of distal reactive lines around the
Symax hip stem, which proves the theoretical concept
of this implant design. With this, distal reactive line
formation could be a useful radiographic sign of good
proximal fixation. The measure of agreement for distal
line formation was only 48% which suggests that this is
not a reproducible and useful radiographic sign for
evaluation. However, this can be explained by the sub-
jective interpretation of the term ‘extensive’ distal line
formation. A better and uniform definition of the term
extensive distal line formation will probably result in a
higher measurement of agreement. This makes this
radiographic sign more useful for evaluation of proxim-
ally fixating uncemented hip stems. The high measure
of agreement for spotweld formation and the absence
of proximal line formation make them useful and reli-
able radiographic features for evaluating these kinds of
stems radiographically over time. The measure of
agreement is more useful to evaluate observer agree-
ment of radiology results compared to Cohen’s Kappa,
as it is not influenced by the prevalence of the evalu-
ated radiographic signs [24]. So, the absence of prox-
imal line formation in combination with progressive
spotweld formation around the coated part and distal
line formation should be interpreted as radiographic
features of good proximal stem fixation.
Although 5 years of clinical follow-up is too short, a
time frame to draw conclusions about final outcome
and the survival rates of the Symax hip stem of 98.8%,
with revision of the stem for any reason as the end
point and with revision of the stem for (a)septic loosen-
ing as the end point of 100%, were excellent and meet
the ‘entry benchmark’ criteria for best prostheses
following the NICE-criteria [38]. These survival rates
correspond to the survival rates of the Symax hip stem
in the Danish Hip Arthroplasty Registry (DHR) of 2013
[39]. In the DHR, the Symax hip stem has a survival
rate of 100% after 5 years with revision for aseptic loos-
ening. The survival rate with revision for any reason is
97.7 to 98.1%, depending on the cup used, after 5 years
[39]. Based on what is known from other older
HA-coated stems, good long-term fixation therefore
can be anticipated.
This study had some limitations. Although it was well
protocolized regarding surgical technique and postop-
erative treatment, some minor differences in treatment
protocol existed between the two centres that can be
interpreted as limitations. Complete excision of the
joint capsule during the inclusion period of this study
was only predominantly performed in centre 1. Surpris-
ingly, capsulectomy did not seem to influence the
occurrence of dislocations in this study, as both centres
had two patients with dislocations. There was no
difference in the amount of heterotopic bone formation
between both study centres, despite the difference in
strategies for prevention of it. Some authors have
reported a decrease in osseointegration of implants
as a result of the use of NSAIDs [40–42], and a non-
significant increase in implant loosening [43]. However,
in line with other reports [44–46], we could not find
signs of a difference in bony fixation on conventional
radiography between the two centres nor was there
more pain reported in one or either centre.
Compared to previous literature of the Symax hip
stem, the fact that only one patient showed migration,
but no loosening, was in line with the EBRA-FCA study
by Buratti et al. [47]. Our results are also in line with the
findings of good clinical performance of this implant as
was reported in a 1 year prospective study, in which the
Symax was compared to the predominantly diaphyseal
anchored Hipstar hip stem (Stryker, Duisburg, Germany)
and the straight Zweymuller (SL-Plus) hip stem (Plus
Orthopedics AG, Rotkreuz, Switzerland) [48]. However,
Bergschmidt et al. discontinued using the Symax hip
stem because of subsidence of more than 10 mm in two
patients and three intraoperative periprosthetic fractures
outside the study group. We cannot confirm these com-
plication frequencies in this current study population
nor in a multicentre prospective cohort of 300 patients.
We therefore do not believe this to be a prosthesis-
related problem.
Conclusions
In summary, excellent mid-term clinical and radio-
graphic performance of the Symax hip stem can be
reported at 5-year clinical follow-up. This is in line with
the design principles and coating properties of this new
stem design. Radiographic features of bone remodeling
and (proximal) stem fixation around this design show
high overall percentage agreement for intra- and
inter-observer reliability, making them useful tools for
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longitudinal follow-up. In view of already available
histological and remodeling data, good long-term per-
formance of the Symax hip stem may be anticipated.
Further confirmation of long-term result is subject of
already initiated follow-up studies of both national and
international prospective cohorts.
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